Understanding the
Unmet Need
Major Safety and
Tolerability Challenges Unnecessary Exposure to
Extended Endocrine Therapy Side Effects Lead
to Noncompliance
About Breast Cancer Index (BCI)
About BCI How is BCI Used? Predictive Studies Prognostic Studies Health Economics Study
Patient Scenarios Ordering Information Videos News & Press
bioTheranostics Privacy Statement Terms and Conditions Site Map

bioTheranostics, Inc.
9640 Towne Centre Drive | Suite 200
San Diego, CA 92121
bioTheranostics.com

US and International: +1 (858) 587-5870
Fax: +1 (858) 587-5874
Client Services: +1 (877) 886-6739
Billing Information: +1 (858) 682-9279

© 2015 bioTheranostics, Inc.
Breast Cancer Index and BCI are service marks of bioTheranostics, Inc.

< Back

Tour the Test Report

Prognostic Score

  • 0 - 10
  • Individualized risk of late recurrence*

*If ordered at time of diagnosis, test report also provides overall (years 0-10), early (0-5 year), and late (5-10 year) risk of recurrence

Prognostic Study PROGNOSTIC STUDIES

Predictive Score

  • Predictive of likelihood of benefit from extended endocrine therapy
  • HIGH or LOW (binary result)
Predictive Study PREDICTIVE STUDIES

Major Safety and Tolerability Challenges

Extended 10-year treatment poses major safety and tolerability challenges1-5

Some patients are unlikely to experience benefit from extended endocrine therapy and may endure years of safety risks and side effects

Results from the ATLAS trial (tamoxifen) expose the benefits and costs of extended endocrine therapy:1

For every 600 women treated with extended endocrine therapy for ER+ early stage breast cancer...

16 Recurrences expected to be prevented

Recurrences expected to be prevented

Serious Complications Expected

Serious Complications Expected

5

endometrial cancers

2

pulmonary emboli

Experienced Side Effects

Experienced Side Effects that impact quality of life

OBCI is the only test which provides clinically actionable information that can impact her treatment plan beyond Year 56

When deciding whether to extend endocrine therapy, also consider:

Unnecessary exposure to extended endocrine therapy Side effects may lead to Noncompliance
Download the BCI Order Form

References

  1. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.
  2. Sgroi DC, et al. Lancet Oncol. Published online September 12, 2013. http://dx.doi.org/10.1016/ S1470-2045(13)70387-5.
  3. Zhang Y, et al. Clin Cancer Res. 2013;19:4196-4205.
  4. Goss PE, et al. N Engl J Med. 2003;349:1793-1802.
  5. Burstein HJ, et al. J Clin Oncol. 2014;32:1-16

Breast Cancer Index Indications for Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.